ALNY
Alnylam Pharmaceuticals margins
- Stocks
- Healthcare
- NASDAQ: ALNY
- Margins
The Alnylam Pharmaceuticals shows a gross margin of 77.3%, an operating margin of 19.5%, an EBITDA margin of 25.5%, and a net margin of 54.3%. Net margin improved the most, by 50.6 percentage points, while gross margin declined the most, by 6.6 percentage points.
ALNY margin history
Over the last 3 years, Alnylam Pharmaceuticals's margins averaged 83.16% gross, 2.55% operating, 5.06% EBITDA, and 0.41% net. Currently, operating, EBITDA, and net margins are above their three-year averages, while gross margin is below its three-year average.
ALNY margin expansion
The largest positive change was in net margin, up 50.6 percentage points. Operating margin also expanded by 11.3 percentage points and Ebitda margin also expanded by 15.4 percentage points, while gross margin contracted by 6.6 percentage points.
ALNY Gross margin
Throughout the last 3 years, Alnylam Pharmaceuticals had an average gross margin of 83.16%. Currently, the current gross margin for Alnylam Pharmaceuticals is 77.3%, 5.9 percentage points below its three-year average. Looking back over the last 3 years, Alnylam Pharmaceuticals's gross margin reached 87% at its highest point in Jun 2024 and 77.3% at its lowest in Sep 2026.
ALNY Operating margin
Looking back over the last 3 years, Alnylam Pharmaceuticals recorded an average operating margin of 2.55%. Alnylam Pharmaceuticals's current operating margin is 19.5% and is 17 percentage points above its three-year average. The highest operating margin for Alnylam Pharmaceuticals was 20.8% in Jun 2026, while the lowest was -15.4% in Dec 2023.
ALNY EBITDA margin
The average EBITDA margin for Alnylam Pharmaceuticals was 5.06% in the last 3 years. The latest EBITDA margin for Alnylam Pharmaceuticals is 25.5%, 20.4 percentage points above its three-year average. The EBITDA margin for Alnylam Pharmaceuticals moved between -14.1% in Dec 2023 and 25.9% in Jun 2026.
ALNY Net margin
Alnylam Pharmaceuticals's net margin averaged 0.41% in the last 3 years. Compared with its three-year average, Alnylam Pharmaceuticals's current net margin is 54.3% and is 53.9 percentage points above its three-year average. Over the last 3 years, Alnylam Pharmaceuticals's net margin peaked at 54.3% in Sep 2026 and reached a low of -24.1% in Dec 2023.
ALNY margin group comparison
With a gross margin of 77.3%, ALNY ranks higher than the Healthcare sector and its peers average but lower than the industry average. In comparison with the Healthcare sector average of 68.4%, Alnylam Pharmaceuticals's gross margin is 13% higher.
ALNY margin peer comparison
Frequently asked questions
What is Alnylam Pharmaceuticals's gross margin?
As of Sep 30, 2026, ALNY has a gross margin of 77.3%.
What is Alnylam Pharmaceuticals's operating margin?
The current operating margin for ALNY is 19.5% as of Sep 30, 2026.
What is Alnylam Pharmaceuticals's EBITDA margin?
As of Sep 30, 2026, ALNY has an EBITDA margin of 25.5%.
What is Alnylam Pharmaceuticals's net margin?
For the period ending Sep 30, 2026, ALNY recorded a net margin of 54.3%.
What are the average margins of ALNY?
Alnylam Pharmaceuticals's gross, operating, EBITDA, and net margins averaged 83.2% gross, 2.6% operating, 5.1% EBITDA, and 0.4% net over the last 3 years.
What are the highest historical margins of ALNY?
Across the 5-year period, ALNY posted its highest margins at 87% gross in Jun 2024, 20.8% operating in Jun 2026, 25.9% EBITDA in Jun 2026, and 54.3% net in Sep 2026.
What are the lowest historical margins of ALNY?
Looking back across 5 years, ALNY reached its lowest margins at 77.3% gross in Sep 2026, -83.9% operating in Dec 2021, -97.3% EBITDA in Sep 2022, and -123% net in Sep 2022.